Eprosartan mesylate, an angiotensin II receptor antagonist

被引:1
|
作者
Qian, Jing-Jing [2 ]
Hu, Xiu-Rong [1 ]
Gu, Jianming [1 ]
Wu, Su-Xiang [2 ]
机构
[1] Zhejiang Univ, Ctr Anal & Measurement, Hangzhou 310028, Zhejiang, Peoples R China
[2] Zhejiang Chinese Med Univ, Coll Pharmaceut Sci, Hangzhou 310053, Zhejiang, Peoples R China
关键词
DOUBLE-BLIND; HYPERTENSION; MULTICENTER; BEHAVIOR;
D O I
10.1107/S1600536811006659
中图分类号
O7 [晶体学];
学科分类号
0702 ; 070205 ; 0703 ; 080501 ;
摘要
The title compound, eprosartan mesylate {systematic name: 2-butyl-1-(4-carboxybenzyl)-5-[(E)-2-carboxy-3-(thiophen-2-yl)prop-1-enyl]-1H-imidazol-3-ium methanesulfonate}, C23H25N2O4S+center dot CH3O3S-, one of the angiotensin II-receptor antagonists, is effective in regulating hypertension, induced or exacerbated by angiotensin II, and in the treatment of congestive heart failure, renal failure and glaucoma. In the eprosartan residue, which appears in this crystal in the cationic imidazolium form, the benzene ring plane is almost orthogonal to that of the imidazole ring, making a dihedral angle of 87.89 (2)degrees. The thiophene ring forms dihedral angles of 66.54 (2) and 67.12 (2)degrees with the benzene and imidazole rings, respectively. The imidazolium NH group and the H atom of the aromatic carboxyl group participate in hydrogen bonds with the the O atoms of the anion, thus forming centrosymmetric aggregates made up of two cations and two anions each. The second carboxyl group further links the above-mentioned aggregates through a conventional centrosymmetric hydrogen-bonding motif into infinite chains along [011].
引用
收藏
页码:O770 / U1389
页数:13
相关论文
共 50 条
  • [21] Effect of ranitidine on the pharmacokinetics of orally administered eprosartan, an angiotensin II antagonist, in healthy male volunteers
    Tenero, DM
    Martin, DE
    Ilson, BE
    Boyle, DA
    Boike, SC
    Carr, AM
    Lundberg, DE
    Jorkasky, DK
    ANNALS OF PHARMACOTHERAPY, 1998, 32 (03) : 304 - 308
  • [22] Antiproteinuric effect of angiotensin II receptor antagonist
    Kajioka, T
    Ueno, M
    Tsuchihashi, T
    Tominaga, M
    Goto, K
    JOURNAL OF HYPERTENSION, 2002, 20 : S366 - S366
  • [23] Orally active angiotensin II receptor antagonist
    Lloyd, AW
    DRUG DISCOVERY TODAY, 1996, 1 (11) : 489 - 489
  • [24] Fimasartan, a novel angiotensin II receptor antagonist
    Kim, Je Hak
    Lee, Joo Han
    Paik, Soo Heui
    Kim, Ji Han
    Chi, Yong Ha
    ARCHIVES OF PHARMACAL RESEARCH, 2012, 35 (07) : 1123 - 1126
  • [25] Structure elucidation and conformational properties of eprosartan a non peptide Angiotensin II AT1 antagonist
    Zoumpoulakis, P
    Grdadolnik, SG
    Matsoukas, J
    Mavromoustakos, T
    JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 2002, 28 (01) : 125 - 135
  • [26] Fimasartan, a novel angiotensin II receptor antagonist
    Je Hak Kim
    Joo Han Lee
    Soo Heui Paik
    Ji Han Kim
    Yong Ha Chi
    Archives of Pharmacal Research, 2012, 35 : 1123 - 1126
  • [27] EFFECT OF ANGIOTENSIN II RECEPTOR ANTAGONIST AND ENDOTHELIN RECEPTOR ANTAGONIST ON NITROGLYCERIN TOLERANCE IN RATS
    张建梅
    陈永红
    王晓红
    唐朝枢
    Chinese Medical Sciences Journal, 2001, (02) : 82 - 85
  • [28] Effect of angiotensin II antagonist eprosartan on hyperglycemia-induced activation of intrarenal renin-angiotensin system in healthy humans
    Osei, SY
    Price, DA
    Laffel, LMB
    Lansang, MC
    Hollenberg, NK
    HYPERTENSION, 2000, 36 (01) : 122 - +
  • [29] Treatment of diabetic nephropathy with angiotensin II receptor antagonist
    E. J. Lewis
    J. B. Lewis
    Clinical and Experimental Nephrology, 2003, 7 (1) : 0001 - 0008
  • [30] Efficacy of an angiotensin II receptor antagonist in managing hyperaldosteronism
    Stokes, GS
    Monaghan, JC
    Ryan, M
    Woodward, M
    JOURNAL OF HYPERTENSION, 2001, 19 (06) : 1161 - 1165